Back to Search Start Over

PGI9 Cost-Effectiveness Comparison of Vedolizumab, Infliximab and Conventional Therapy for the Treatment of Biologic-Naïve, Moderately to Severely ACTIVE Ulcerative Colitis Patients in China.

Authors :
Sheng, Y.
Ma, L.
Chen, J.
Xie, L.
Zhao, W.
Han, Y.
Source :
Value in Health. 2020 Supplement 2, Vol. 23, pS534-S534. 1p.
Publication Year :
2020

Subjects

Subjects :
*ULCERATIVE colitis
*VEDOLIZUMAB
*INFLIXIMAB
*COST effectiveness
*THERAPEUTICS

Details

Language :
English
ISSN :
10983015
Volume :
23
Database :
Academic Search Index
Journal :
Value in Health
Publication Type :
Academic Journal
Accession number :
160980291
Full Text :
https://doi.org/10.1016/j.jval.2020.08.775
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details